TY - JOUR
T1 - Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance
AU - Castillo, Jorge J.
AU - Gertz, Morie A.
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/4/3
Y1 - 2017/4/3
N2 - In recent years, the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy. However, the risk of secondary malignancies has increased, thought to be due to a combination of environmental and disease-related factors, as well as treatment. In the present review, we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenström macroglobulinemia (WM). Patients with MGUS appear to have a higher risk of developing myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In patients with MM, the risk of AML, acute lymphoblastic leukemia and some solid tumors appears increased. Finally, in WM patients, there seems to be increased risk of AML, diffuse large B-cell lymphoma, thyroid cancer and melanoma.
AB - In recent years, the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy. However, the risk of secondary malignancies has increased, thought to be due to a combination of environmental and disease-related factors, as well as treatment. In the present review, we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenström macroglobulinemia (WM). Patients with MGUS appear to have a higher risk of developing myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In patients with MM, the risk of AML, acute lymphoblastic leukemia and some solid tumors appears increased. Finally, in WM patients, there seems to be increased risk of AML, diffuse large B-cell lymphoma, thyroid cancer and melanoma.
KW - MGUS
KW - Myeloma
KW - Waldenström macroglobulinemia
KW - secondary malignancies
UR - http://www.scopus.com/inward/record.url?scp=84983543808&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983543808&partnerID=8YFLogxK
U2 - 10.1080/10428194.2016.1217527
DO - 10.1080/10428194.2016.1217527
M3 - Review article
C2 - 27546465
AN - SCOPUS:84983543808
SN - 1042-8194
VL - 58
SP - 773
EP - 780
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 4
ER -